Ozette
Financials
Estimates*
USD | 2022 | 2023 |
---|---|---|
Revenues | 2.1m | 4.2m |
% growth | - | 100 % |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$6.0m | Seed | ||
* | $26.0m | Series A | |
Total Funding | CAD43.6m |
Related Content
Recent News about Ozette
EditOzette is a startup that operates in the biotechnology sector, specifically focusing on the analysis of single-cell data. The company's primary goal is to enhance the understanding of the human immune system and its complexities. This is achieved through the use of artificial intelligence (AI) to analyze cellular data, which can potentially lead to the discovery of new therapies and advancements in medical treatment.
Ozette's clients are primarily research and clinical development organizations, including pharmaceutical companies and academic institutions. The company collaborates with these partners to analyze biological samples or previously generated data, aiming to provide maximum insight and value from this information.
The business model of Ozette is based on providing AI-driven computational analysis technology to its partners. This technology helps reveal distinct T cell populations that suppress immune effectiveness in the tumor microenvironment, which can inform drug development in immuno-oncology. The company generates revenue by offering these data analysis services to its partners.
In summary, Ozette is a biotech startup that uses AI to analyze single-cell data, aiming to advance medical research and therapy development. The company collaborates with research and clinical development organizations, providing them with valuable insights from their data.
Keywords: Biotechnology, Single-cell data analysis, Artificial Intelligence, Immune system, Medical research, Therapy development, Pharmaceutical companies, Academic institutions, Tumor microenvironment, Immuno-oncology.